期刊文献+

IL18-IL2融合基因的克隆及其在大肠埃氏菌(E.coli)中的表达

Cloning and Expression of a Fusion Protein IL18-IL2 in Escherichia Coli
下载PDF
导出
摘要 构建IL-18和IL-2成熟区的融合基因IL18-IL2,并实现其在大肠埃氏菌中的大量表达.抽提经PHA刺激增殖的人淋巴细胞总RNA,RT-PCR法获得IL-18和IL-2基因的成熟区序列,并通过一段Linker相连得到融合基因IL18-IL2;将IL18-IL2克隆至原核表达载体pBV220,并转化至大肠埃氏菌BL21(DE3);阳性克隆经42℃温度诱导表达后用SDS-PAGE和Western blot分析重组蛋白的表达情况及正确性.经SDS-PAGE分析,融合基因IL18-IL2在宿主菌中能够表达,其相对表观分子质量约为34.5 kD;Western blot进一步证明重组蛋白正确.实验结果表明,已成功构建了表达人IL18-IL2的菌株,为进一步研究融合蛋白IL18-IL2体内外抗肿瘤活性提供了基础. We report here the cloning and expressing of an fusion protein IL18-IL2 containing the mature hu-man interleukin-18 peptide and interleukin-2 peptide in Escherichia Coli.The mature human IL-18 and IL-2cDNAs are cloned by RT-PCR with the total RNAs,extracted from human PBMC stimulated by PHA,as tem-plates.The fusion gene IL18-IL2 connected by a flexible linker is inserted into the pBV220 expression vector and sequenced.Then the recombinant plasmid pBV-IL18-IL2 is transformed into BL21(DE3) and induced at 42 ℃.SDS-PAGE analysis indicates that the relative molecular weight of IL18-IL2 is about 34.5 ku and Western blot further confirms its correctness.The fusion protein IL18-IL2 is successfully cloned and expressed in E.coli.This work has settled the foundation for further biological research on IL18-IL2.
机构地区 烟台大学药学院
出处 《烟台大学学报(自然科学与工程版)》 CAS 北大核心 2011年第2期116-120,共5页 Journal of Yantai University(Natural Science and Engineering Edition)
基金 烟台大学青年基金资助项目(YX08Z3)
关键词 白细胞介素-18 白细胞介素-2 pBV220载体 原核表达 融合蛋白 interleukin-18 interleukin-2 pBV220 vector prokaryotic expression fusion protein
  • 相关文献

参考文献9

  • 1Gaffen S L, Liu K D. Overview of interleukin - 2 func- tion, production and clinical applications [ J]. Cytokine,2004, 28(3) :109-123.
  • 2Ushio S, Namba M, Okura T, et al. Cloning of the cD- NA for human IFN-3,-inducing factor, expression in Escherich- ia coli, and studies on the biologic activities of the protein [ J ]. J Immunol, 1996,156 ( 11 ) :4274-4279.
  • 3Smyth M J,Swann J,Kelly J M,et al. NKG-D recogni- tion and perforin effector function mediate effective cytokine immunotherapy of cancer [ J ]. J Exp Med, 2004,200 ( 10 ) : 1325-1335.
  • 4Negrier S, Maral J, Drevon M, et al. Long-term follow- up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe [ J ]. Cancer J Sci Am,2000,6( Suppll ):93-98.
  • 5Atkins M B,Kunkel L,Sznol M,et al. High-dose re- combinant interleukin-2 therapy in patients with metastatic melanoma:long-term survival update [ J ]. Cancer J Sci Am, 2000,6 ( Suppl 1 ) : 11-14.
  • 6Peest D,Leo R,Deicher H. Tumor-directed cytotoxicity in multiple myeloma--the basis for an experimental treatment approach with interleukin-2 [ J ].Stem Ceils, 1995,13 ( Suppl 2) :72-76.
  • 7Tomura M,Zhou X Y,Maruo S,et al. A critical role for IL-18 in the proliferation and activation of NK1. 1 + CD3-cells [ J ]. J Immunol, 1998,160 ( 10 ) :4738-4746.
  • 8Gu Y,Kuida K,Tsutsui H,et al. Activation of interfer- on-γ inducing factor mediated by interlrukin-1 β converting enzyme [ J ]. Science, 1997,275 (5297) : 206-209.
  • 9Sone S R, Ogura T. Local interleukin-2 therapy for cancer,and its effector induction mechnism [ J ]. Oncology, 1994,51 (2) : 170-176.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部